Arvinas (ARVN) Cash from Investing Activities (2017 - 2026)
Arvinas (ARVN) recorded quarterly Cash from Investing Activities of $13.7 million in Q1 2026, down 90.6% quarter-over-quarter from $145.8 million in Q4 2025, and down 80.29% on a YoY basis from $69.5 million in Q1 2025.
Arvinas (ARVN) Cash from Investing Activities (2017 - 2026) Analysis & Trends
Arvinas' Cash from Investing Activities history runs 10 years deep, the most recent figure standing at $13.7 million for Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 80.29% year-over-year to $13.7 million; the TTM figure through Mar 2026 stood at $351.8 million (up 51.64% YoY), while the FY2025 annual figure was $407.6 million, up 1074.64% from the prior year.
- Cash from Investing Activities was $13.7 million for Q1 2026 at Arvinas, down from $145.8 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $145.8 million in Q4 2025 to a low of -$127.8 million in Q1 2024.
- Historically, Cash from Investing Activities has averaged $53.1 million across 5 years, with a median of $63.5 million in 2025.
- Biggest YoY gain for Cash from Investing Activities was 1511.63% in 2023; the steepest drop was 376.8% in 2023.
- A 5-year view of Cash from Investing Activities shows it stood at $19.4 million in 2022, then slumped by 376.8% to -$53.7 million in 2023, then surged by 284.17% to $98.9 million in 2024, then jumped by 47.42% to $145.8 million in 2025, then tumbled by 90.6% to $13.7 million in 2026.
- The last three Cash from Investing Activities figures came in at $13.7 million (Q1 2026), $145.8 million (Q4 2025), and $63.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Arvinas | 492.16 Mn | -122.74 Mn | - | 13.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.70 Mn |
| Mar 31, 2026 | 13.70 Mn |
| Dec 31, 2025 | 145.80 Mn |
| Dec 31, 2025 | 145.80 Mn |
| Sep 30, 2025 | 63.50 Mn |
| Sep 30, 2025 | 63.50 Mn |
| Jun 30, 2025 | 128.80 Mn |
| Jun 30, 2025 | 128.80 Mn |
| Mar 31, 2025 | 69.50 Mn |
| Mar 31, 2025 | 69.50 Mn |
| Dec 31, 2024 | 98.90 Mn |
| Dec 31, 2024 | 98.90 Mn |
| Sep 30, 2024 | 50.50 Mn |
| Sep 30, 2024 | 50.50 Mn |
| Jun 30, 2024 | 13.10 Mn |
| Jun 30, 2024 | 13.10 Mn |
| Mar 31, 2024 | -127.80 Mn |
| Mar 31, 2024 | -127.80 Mn |
| Dec 31, 2023 | -53.70 Mn |
| Dec 31, 2023 | -53.70 Mn |